Genvor Secures Full Ownership of ~9,000-Peptide Library From Founder/CSO Ahead of Nasdaq Push
GNVR filed a Corporate Governance and Compliance on light trading volume (0.3× avg).
Summary
Genvor's founder and CSO assigned the company's ~9,000-peptide library and related data to Genvor in all fields, a step the filing ties to a proposed underwritten offering and Nasdaq listing. No cash or share consideration is involved, but USDA-ARS co-owns five of the listed patents.
Key Events · Corporate Governance and Compliance · GNVR
-
Founder Assigns Peptide Library to Genvor
Dr. Jesse Jaynes, co-founder, director and Chief Scientific Officer, assigned the Library — approximately 9,000 antimicrobial peptides plus design, screening, activity, formulation and validation data — to Genvor in all fields under an agreement dated October 21, 2026.
-
Narrow Academic License Flows Back
Jaynes receives a personal, non-exclusive, royalty-free, perpetual license limited to academic research in the Jaynes Fields; improvements made using BioCypher or in the Company Fields belong to Genvor.
-
USDA-ARS Co-Owns Five Patents
Schedule C discloses USDA-ARS co-ownership of U.S. Patents 11,083,775, 11,690,894, 12,138,294 and 12,458,684 plus Application 19/377,178 under CRADA No. 58-6054-8-010, so third-party confirmations or licenses may still be needed.
-
Tied to Offering and Nasdaq Listing
The agreement recites that the parties acted in connection with the Company's proposed underwritten public offering and Nasdaq listing, positioning the IP ownership as diligence-ready.
Analysis · GNVR · Industrial Applications And Services
Genvor has locked down the intellectual property underpinning its BioCypher peptide-design platform. Founder, director and Chief Scientific Officer Dr. Jesse Jaynes assigned the Library — roughly 9,000 antimicrobial peptides plus the associated design, screening and validation data — to the Company in all fields, with only a narrow academic license flowing back to him. According to the filing, the agreement was signed to confirm ownership in connection with a proposed underwritten public offering and Nasdaq listing, a cleanup of the corporate story that underwriters and exchange reviewers would otherwise flag as a diligence gap. The caveats are real: Jaynes warrants sole ownership only 'to the best of his knowledge,' and Schedule C discloses USDA-ARS co-ownership of five patents and applications, so the Company may still need third-party confirmations or licenses. No cash changes hands and no shares are issued — this is an ownership confirmation, not a financing.
How filings like this one have moved
In the 30 days to Oct 26, 2026, 29.9% of the 1374 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.12%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GNVR was trading at $0.75 on OTC in the Industrial Applications And Services sector, with a market capitalization of approximately $27.3M. The 52-week trading range was $0.00 to $10.01. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.